Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Bioxyne.
RELATED STOCKHEAD STORIES
Health & Biotech
Bioxyne subsidiary granted upgraded wholesale licence for MDMA and psilocybin finished products
Health & Biotech
‘Monumental’– Bioxyne subsidiary awarded Australia’s first GMP licence to manufacture psilocybin and MDMA
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Aussie stocks dive as big miners dig a great hole through Monday
News
ASX Small Caps Lunch Wrap: Who was running really, really late to work today?
News
Top 10 at 10: Legal mushrooms? The party is at Bioxyne’s house
News
In Case You Missed It: Key approvals for resource plays and Aroa looks to improve mastectomy surgery
Health & Biotech
Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth
Health & Biotech
Bioxyne subsidiary unveils platform for transparent pricing in Australia’s B2B medical cannabis market
Health & Biotech
The ASX stocks hoping to profit from the endless search for an ‘elixir of youth’
Health & Biotech
Why these ASX firms are shying away from the ‘pot stock’ label – Part One
News
Quarterly Wrap: Pot stocks shine with record revenues for Melodiol, 75pc increase in revenue for Bioxyne
News
In Case You Missed It: O&G production, a graphite plant and a Chilean gold anomaly
Health & Biotech
Bioxyne subsidiary imports $3.2million of premium quality cannabis flower into Australia
News
Top 10 at 11: Not a lot of movement, but there’s not a whole lot of news.
Health & Biotech
These are the ASX stocks Morgans thinks can push the health and wellness agenda
Health & Biotech
